LUCAR-DKS1 for severe autoimmune diseases
Part of Immune system & allergy clinical trials.
This early-phase trial tests an experimental treatment called LUCAR-DKS1, which uses your own immune cells to target and control severe autoimmune diseases like lupus, vasculitis, and scleroderma that haven't responded to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between ages 18 and 70.
- You must have one of these autoimmune diseases: SLE (lupus), AAV (a type of blood vessel inflammation), systemic sclerosis (scleroderma), inflammatory muscle disease (myositis), or Sjögren's syndrome.
- Your disease must be relapsed or refractory, meaning it hasn't gotten better with standard treatments or has come back.
- You must test positive for CD19 or BCMA markers on your immune cells.
- You must not have had a previous treatment with your own modified immune cells (car T cell therapy).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using your own immune cells (CAR T-cells) targeted at a marker called CD19. It is for people whose lupus or myositis has not been controlled by other treatments.
This trial tests a new type of immune cell therapy using modified natural killer cells (CAR-NK) that target a protein called CD19 and produce helpful signals (IL-10 and IL-15). It is for people with certain autoimmune diseases that have not improved with standard treatments or have come back after getting better.
This study tests a new drug called RXIM002 for people with severe autoimmune diseases that haven't improved with standard treatments. It aims to see if targeting immune cells with the CD19 marker can help control the disease.
This trial tests an investigational drug called OL-108 for people with certain autoimmune diseases (lupus, myositis, scleroderma, or vasculitis) that have come back or not responded to standard treatments. The goal is to see if it's safe and if it can help control the disease.
This trial tests an investigational cell therapy called NKX019 for people with certain autoimmune diseases like scleroderma, myositis, vasculitis, or rheumatoid arthritis. It aims to see if NKX019 can help control the disease when standard treatments have not worked well enough.
This trial tests a new cell therapy, CD19 UCAR-T cells, to see if it can help people with certain autoimmune diseases like lupus or scleroderma that haven't improved with standard treatments. It aims to reset the immune system by targeting and removing faulty B cells.
Hear when a new Relapsed/Refractory Autoimmune Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.